Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

ARCA Biopharma, Inc.115 enrolled

Overview

This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

115

Conditions

Catheters, Indwelling

Interventions

AlfimepraseDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Subjects must: * have a dysfunctional Central Venous Access Device (CVAD) defined as unable to withdraw 3 mL blood * have had the device in place for \> 48 hours * be clinically stable * be 18 or older * give informed consent

Locations (1)

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.